Obtained from a previously described hit28 by means of a structural improvement, pursued through a rational approach facilitated by preliminary docking studies, the novel compounds are able to target two key protein kinases accountable for both pathogenesis and progression of melanoma. The gene discussed is WEE1; the disease is melanoma.